Search results for "ECL"

showing 10 items of 1262 documents

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic …

2016

[Purpose] TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P < 0.001]. The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup.

Male0301 basic medicineOncologyCancer ResearchPyrrolidinesColorectal cancerTrifluridineHelsinki declarationlaw.inventionTrifluridinechemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicineAged 80 and overMetastatic colorectal cancerPalliative CareHazard ratioGeneral MedicineMiddle AgedPrognosisTAS-102Survival RateDrug CombinationsOncology030220 oncology & carcinogenesisDrug Therapy CombinationFemaleColorectal NeoplasmsFluoropyrimidineResearch Articlemedicine.drugAdultmedicine.medical_specialtyanimal structuresSubgroup analysisPlaceboAntiviral Agents03 medical and health sciencesDouble-Blind MethodInternal medicineHumansTipiracil hydrochlorideUracilAgedNeoplasm StagingTipiracilbusiness.industrymedicine.diseaseSurgery030104 developmental biologychemistrySpainbusinessThymineFollow-Up StudiesClinical and Translational Oncology
researchProduct

Genetic systems for a new approach to risk of progression of diabetic retinopathy.

2016

OBJECTIVE: To evaluate the risk of progression of diabetic retinopathy (DR) using new strategies to obtain genetic information in type 2 diabetes (T2D) based on interfering ribonucleic acid (RNA). MATERIAL AND METHODS: A prospective multicentre case-control study of 132 participants was distributed into: T2D with (+DR) or without (-DR) (T2DG; n=77), and a control group (CG; n=55). After an eye examination and personal interview, tears were collected for molecular analysis (expression of microRNAs [miRNAs] (miRCURY ARN Isolation Kit, Qiagen)]. Libraries, 137 vs. 140bp (GeneMapper, Applied Biosystems), were obtained in 18 samples (T2DG+DR=6; T2DG-DR=6; CG=6) by performing next-generation sequ…

Male0301 basic medicineOncologyMicro RNAsmedicine.medical_specialtyBiomarcadores preclinicosType 2 diabetesMicro-ARNBioinformaticsRisk AssessmentInterference by RNA03 medical and health sciencesDiabetic retinopathyInternal medicineType 2 diabetes mellitusmedicineHumansProspective StudiesFamily historyAgedDiabetic Retinopathymedicine.diagnostic_testSequence Analysis RNAbusiness.industryPre-clinical biomarkersType 2 Diabetes MellitusGenetic systemsRetinopatia diabeticaGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseInterferencia por ARNMolecular analysisDiabetes mellitus tipo 2030104 developmental biologyDiabetes Mellitus Type 2Eye examinationCase-Control StudiesDisease ProgressionTearsFemalebusinessBiomarcadores preclínicos Diabetes mellitus tipo 2 Diabetic retinopathy Interference by RNA Interferencia por ARN Micro RNAs Micro-ARN Pre-clinical biomarkers Retinopatía diabética Type 2 diabetes mellitus
researchProduct

Both cholestatic and steatotic drugs trigger extensive alterations in the mRNA level of biliary transporters in rat hepatocytes: Application to devel…

2016

Disruption of the vectorial bile acid transport in the liver is a key feature of cholestatic drugs, although many causal and mechanistic aspects are still unknown. The aim of the present study was to explore if cholestatic drugs can repress or induce the expression of hepatic transporters. To this end, sandwich-cultured rat hepatocytes were treated with cholestatic and non-cholestatic (steatotic, non-hepatotoxic, etc.) drugs and the mRNA expression of 10 uptake and efflux biliary transporters was measured. Results evidenced that all cholestatic drugs cause extensive alterations in the mRNA expression of most biliary transporters. Surprisingly, nearly all steatotic drugs also affected the ex…

Male0301 basic medicinePathologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsDrug Evaluation PreclinicalOrganic Anion Transporters Sodium-IndependentPharmacologyBiologyToxicology030226 pharmacology & pharmacyRats Sprague-Dawley03 medical and health sciences0302 clinical medicineCholestasisPredictive Value of TestsIn vivomedicineAnimalsBileRNA MessengerCells CulturedCholestasisMultidrug resistance-associated protein 2Fatty liverTransporterGeneral Medicinemedicine.diseaseRatsFatty Liver030104 developmental biologyTetracyclinesHepatocytesBiomarker (medicine)EffluxSteatosisCarrier ProteinsBiomarkersToxicology Letters
researchProduct

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

2017

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in type 2 diabetes mellitus (T2DM). The overarching hypothesis is that hyperglycemia and glucotoxicity are upstream of all other complications seen in diabetes. The aim of this study was to investigate effects of empagliflozin on glucotoxicity, β-cell function, inflammation, oxidative stress and endothel…

Male0301 basic medicineendocrine system diseasesDiabetic CardiomyopathiesFPS-ZM1 RAGE inhibitorClinical BiochemistryAorta ThoracicRAGE receptor for AGEICAM-1 intercellular adhesion molecule-1ECL enhanced chemiluminescence030204 cardiovascular system & hematologyDPP-4 dipeptidyl peptidase-4medicine.disease_causeTNF-α tumor necrosis factor-αBiochemistryeNOS endothelial •NO synthase (type 3)0302 clinical medicineGlucosidesecSOD extracellular superoxide dismutaseInsulin-Secreting CellsCCL-2 see MCP-1HyperlipidemiaHyperinsulinemiaGTN glyceryl trinitrate (nitroglycerin)IFN-γ interferon-γDHE dihydroethidineEndothelial dysfunctionEndothelial dysfunctionIL-6 interleukin-6lcsh:QH301-705.5HO-1 heme oxygenase-1lcsh:R5-920ICAM-1NG normoglycemiaDiabetesNox catalytic subunit of NADPH oxidaseSGLT2 inhibitorβ-cell contentL-012 8-amino-5-chloro-7-phenylpyrido[34-d]pyridazine-14-(2H3H)dione sodium saltChIP chromatin immunoprecipitationC-Reactive ProteinCRP C-reactive proteinAGE advanced glycation end productsHbA1c glycohemoglobinlcsh:Medicine (General)Research PaperZucker diabetic fatty ratsmedicine.medical_specialtyDMSO dimethylsulfoxideMCP-1 monocyte-chemoattractant-protein-1qRT-PCR quantitative reverse transcription polymerase chain reactionZDF Zucker diabetic fatty (rat)Low-grade inflammation03 medical and health sciencesROS reactive oxygen speciesSodium-Glucose Transporter 2Physiology (medical)Internal medicineDiabetes mellitusPKC protein kinase CEmpagliflozinmedicineAnimalsHypoglycemic AgentsBenzhydryl CompoundsCOX2 cyclooxygenase-2SGLT2i SGLT2 inhibitorSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinACh acetylcholinebusiness.industryOrganic Chemistrynutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseH2K9me2 histone3 lysine9 dimethylationRatsRats ZuckerDHFR dihydrofolate reductaseSGLT2 sodium-glucose co-transporter-2Oxidative StresssGC soluable guanylyl cyclaseGlucose030104 developmental biologyEndocrinologylcsh:Biology (General)ALDH-2 mitochondrial aldehyde dehydrogenaseEndothelium VascularAGE/RAGE signalingHG hyperglycemiabusinessOxidative stressRedox Biology
researchProduct

Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high fat diet

2016

Previous studies suggested that endogenous glucagon-like peptide 2 (GLP-2) is dispensable for the regulation of glucose homeostasis under normal conditions, while it can play a beneficial role in obesity conditions. The purpose of the present study was to investigate whether chronic treatment with Gly2-GLP-2, a stable analogue of GLP-2, can have an impact on glycaemic and lipid control in mice fed a high-fat diet (HFD), an animal model of human obesity and insulin resistance. HFD mice were treated once a day with Gly2-GLP-2 for 4 weeks. Body weight, food intake, fasting glucose, intraperitoneal glucose tolerance, insulin-induced glucose clearance, glucose-stimulated insulin secretion, β-cel…

Male0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDrug Evaluation PreclinicalMicrovesicular SteatosisCarbohydrate metabolismDiet High-FatSettore BIO/09 - FisiologiaRandom Allocation03 medical and health sciencesEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusGlucagon-Like Peptide 2medicineAnimalsGlucose homeostasisObesityPancreasPancreatic islets.Glucose Metabolism Disordersbusiness.industrydigestive oral and skin physiologyInsulin resistancemedicine.diseaseGlucagon-like peptide-2LipidsObesityMice Inbred C57BL030104 developmental biologyEndocrinologyLiverPeptidesbusinessGLP-2Dyslipidemia
researchProduct

Association Between Atrophy of the Caudate Nuclei, Global Brain Atrophy, Cerebral Small Vessel Disease and Mild Parkinsonian Signs in Neurologically …

2017

Background: Mild Parkinsonian signs (MPS) are commonly seen in aging, and have been related to cerebral Small Vessel Diseases (SVD) with no univocal results. Objective: The aim of this study was to investigate the cross-sectional relation between MPS and White Matter Hyperintensities (WMH), lacunes, caudate atrophy, and global cerebral atrophy in a large cohort of Neurologically and Cognitively Healthy (NCH) aging individuals. Method: 1,219 NCH individuals were included in the analysis, and underwent standard brain MRI. The items of the motor section of the Unified Parkinson’s Disease Rating Scale were used to evaluate tremor, rigidity, bradykinesia, and gait/balance/axial dysfunction. Cau…

Male0301 basic medicinemedicine.medical_specialtyNeurologyNeuropsychological TestsCohort Studies03 medical and health sciencesLateral ventricles0302 clinical medicineAtrophyInternal medicineGlobal brain atrophyBasal gangliaHumansMedicineCognitive declineAgedUltrasonographyAged 80 and overCerebral atrophybusiness.industryHeartParkinson DiseaseMiddle AgedMental Status and Dementia Testsmedicine.diseaseMagnetic Resonance ImagingHyperintensityCross-Sectional Studies030104 developmental biologyNeurologyCerebral Small Vessel DiseasesCardiologyFemaleNeurology (clinical)AtrophyCaudate Nucleusbusiness030217 neurology & neurosurgeryCurrent Alzheimer Research
researchProduct

Electrocortical networks in Parkinson's disease patients with Mild Cognitive Impairment. The PaCoS study

2019

Abstract Introduction Parkinson's Disease (PD) is frequently associated with cognitive dysfunction ranging from Mild Cognitive Impairment (PD-MCI) to dementia. Few electrophysiological studies are available evaluating potential pathogenetic mechanisms linked to cognitive impairment in PD since its initial phases. The objective of the study is to analyze electrocortical networks related with cognitive decline in PD-MCI for identifying possible early electrophysiological markers of cognitive impairment in PD. Methods From the PaCoS (Parkinson's disease Cognitive impairment Study) cohort, a sample of 102 subjects including 46 PD-MCI and 56 PD with normal cognition (PD-NC) was selected based on…

Male0301 basic medicinemedicine.medical_specialtyParkinson's diseaseQuantitative EEGElectroencephalographyAudiology03 medical and health sciences0302 clinical medicinemental disordersmedicineHumansDementiaCognitive DysfunctionNeuropsychological assessmentCognitive declineTomographyAgedElectrocortical networkElectrocortical networksmedicine.diagnostic_testbusiness.industryParietal lobeMild cognitive impairmentElectroencephalographyParkinson DiseaseCognitionMiddle Agedmedicine.disease030104 developmental biologyNeurologyFrontal lobeDisease ProgressionFemaleNeurology (clinical)Nerve NetElectrocortical networks; Mild cognitive impairment; Parkinson's disease; Quantitative EEG; Neurology; Geriatrics and Gerontology; Neurology (clinical)Geriatrics and GerontologyOccipital lobebusiness030217 neurology & neurosurgeryParkinsonism &amp; Related Disorders
researchProduct

Subclinical levels of anxiety but not depression are associated with planning performance in a large population-based sample

2017

BackgroundMajor depression and anxiety disorders are known to negatively influence cognitive performance. Moreover, there is evidence for greater cognitive decline in older adults with generalized anxiety disorder. Except for clinical studies, complex executive planning functions and subclinical levels of anxiety have not been examined in a population-based sample with a broad age range.MethodsPlanning performance was assessed using the Tower of London task in a population-based sample of 4240 participants aged 40–80 years from the Gutenberg Health Study (GHS) and related to self-reported anxiety and depression by means of multiple linear regression analysis.ResultsHigher anxiety ratings we…

Male050103 clinical psychologymedicine.medical_specialtyGeneralized anxiety disorderPopulationAnxietyNeuropsychological TestsExecutive Function03 medical and health sciencesCognition0302 clinical medicineGermanyHumansMedicineCognitive Dysfunction0501 psychology and cognitive sciencesProspective StudiesEffects of sleep deprivation on cognitive performanceCognitive declineeducationPsychiatryProblem SolvingApplied PsychologyDepression (differential diagnoses)AgedSubclinical infectioneducation.field_of_studyDepressionbusiness.industry05 social sciencesCognitionMiddle Agedmedicine.disease030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesLinear ModelsAnxietyFemalemedicine.symptombusinessPsychomotor PerformanceClinical psychologyPsychological Medicine
researchProduct

18F-Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification.

2019

Background and purpose While AD can be definitively confirmed by postmortem histopathologic examination, in vivo imaging may improve the clinician's ability to identify AD at the earliest stage. The aim of the study was to test the performance of amyloid PET using new processing imaging algorithm for more precise diagnosis of AD. Methods Amyloid PET results using a new processing imaging algorithm (MRI-Less and AAL Atlas) were correlated with clinical, cognitive status, CSF analysis, and other imaging. The regional SUVR using the white matter of cerebellum as reference region and scores from clinical and cognitive tests were used to create ROC curves. Leave-one-out cross-validation was carr…

Male18F-florbetabenAmyloidSensitivity and SpecificityAmyloid-PET Imaging030218 nuclear medicine & medical imagingWhite matter03 medical and health sciences0302 clinical medicineAlzheimer DiseasePositron Emission Tomography Computed Tomographymental disordersStilbenesmedicineImage Processing Computer-AssistedDementiaHumansRadiology Nuclear Medicine and imaging18F-florbetaben; Alzheimer's disease; Amyloid-PET Imaging; MR-lessAgedRetrospective StudiesPET-CTAniline CompoundsReceiver operating characteristicbusiness.industry18F-florbetaben Alzheimer's disease Amyloid-PET Imaging MR-less Aged Alzheimer Disease Female Humans Image Processing Computer-Assisted Magnetic Resonance Imaging Male Positron Emission Tomography Computed Tomography Retrospective Studies Sensitivity and Specificity Aniline Compounds StilbenesAlzheimer's diseasemedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureMR-lessFemaleNeurology (clinical)Differential diagnosisNuclear medicinebusiness030217 neurology & neurosurgeryPreclinical imagingFrontotemporal dementiaJournal of neuroimaging : official journal of the American Society of Neuroimaging
researchProduct

Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.

2016

Background Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and bone strength. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to progressive muscle degeneration and also high incidence of fractures. The aim of our study was to test whether inhibition of activin receptor IIB ligands with or without exercise could improve bone strength in the mdx mouse model for DMD. Methods Thirty-two mdx mice were divided to running and non-running groups and to receive either PBS control or soluble activin type IIB-receptor (ActRIIB-Fc) once weekly for 7 weeks. Results Treatment of mdx mice with ActRIIB-Fc resulted in significantly in…

MaleActivin Receptors Type IIDrug Evaluation PreclinicalOsteoclastsBone μCTBone and BonesMiceTGF-βsBone DensityPhysical Conditioning AnimalAnimalsBone ResorptionMuscle SkeletalExerciseOsteoblastsOrgan SizeMuscular Dystrophy AnimalCombined Modality TherapyBone-muscle interactionsAnimal modelsMice Inbred C57BLMuscular Dystrophy DuchenneDisease Models AnimalSolubilityMice Inbred mdxResearch ArticleBMC musculoskeletal disorders
researchProduct